Global and China DNA Sequencing Industry Research Report, 2014-2017
- Hard Copy
- Single User License
- Enterprise-wide License
(PDF Printable & Editable)
- Hard Copy + Single User License
DNA sequencing is the process of reading nucleotide bases in a specific DNA molecule, that is to say determining the arrangement mode of adenine, thymine, cytosine, and guanine. It can be applied in a broad range of fields, including medicine, biology, geology, and agriculture.
With the advancement of DNA sequencing technology and dramatic decline in sequencing costs, DNA sequencing is increasingly showing its market potential in noninvasive detection, disease diagnosis, and personalized treatment. In 2013, the market size of global DNA sequencing (including equipment and consumables, service and workflow, etc.) approximated USD4.6 billion, up around 26% from the previous year. It is projected that by 2017 this figure will reach USD10.096 billion, exceeding USD10 billion for the first time.
Ever since 1975, DNA sequencing technology has been through four generations, but the fourth-generation technology—Nanopore sequencing is still under development. Due to technologies and costs, the second-generation high-throughput sequencers are the mainstream sequencing platform around the world, with its total number occupying over 95% of next-generation DNA sequencers worldwide.
The upstream sectors of DNA sequencing industry are extremely robust, with the global market dominated by the second-generation DNA sequencing enterprises including Illumina, Thermo Fisher Scientific (through Life Technologies), Roche and the third-generation sequencing enterprises such as Pacific Biosciences. A review of these giants’ development history shows that mergers and acquisitions are the main driving forces behind the great market power. In February 2014, Thermo Fisher Scientific acquired Life Technologies for USD13.6 billion, making it the industry giant second only to Illumina.
In China, the upstream sectors of DNA sequencing industry are virtually monopolized by foreign giants. BGI is the leader in China’s DNA sequencing service, and its second-generation DNA sequencers top the global chart in number. However, two of its sequencers—HiSeq 2000 and Ion Proton were entirely from Illumina and Life Technologies. In March 2013, BGI acquired Complete Genomics, a sign that BGI formally ventured into the upstream sectors of DNA sequencing industry. In June 2014, BGI’s two products—BGISEQ-1000 and BGISEQ-100 became the first second-generation DNA sequencers registered in China.
It is expected, however, that within the next five years the weak position of Chinese enterprises in upstream sectors will remain unchanged except for the epic M&A.
Global and China DNA Sequencing Industry Research Report, 2014-2017 mainly focuses on the followings:
Features, cost, etc. of DNA sequencing technology;
Major M&As, genetic database, market size and structure, etc. of global DNA sequencing industry;
Development, industry policies, market structure and prospects, etc. of DNA sequencing industry in China;
Operation, DNA sequencing business, etc. of 12 enterprises at home and abroad.
1. Overview of DNA Sequencing Industry
1.2 Industry Chain
1.4 Development History and Technical Features
2. Global DNA Sequencing Industry
2.1 Industry Chain Layout of Major Enterprises
2.2 Major M&As
2.3 Genetic Database
2.5 Market Size and Prospects
3. China DNA Sequencing Industry
3.2 Policy Environment
3.3 Market Structure
4. Key Enterprises
4.1.3 Revenue Structure
4.1.4 Gross Margin
4.1.5 R&D and Investment
4.1.6 DNA Sequencing
4.1.7 Development Prospects
4.2 Thermo Fisher Scientific
4.2.3 Revenue Structure
4.2.4 Operating Margin
4.2.5 R&D and Investment
4.2.6 DNA Sequencing
4.2.7 Development in China
4.2.8 Development Prospects
4.3.3 DNA Sequencing
4.4.2 DNA Sequencing
4.5.3 Revenue Structure
4.5.5 DNA Sequencing
4.6 Pacific Biosciences
4.6.3 Revenue Structure
4.6.5 DNA Sequencing
4.7.3 Revenue Structure
4.7.4 Operating Margin
4.7.6 DNA Sequencing
4.8 DAAN Gene
4.8.3 Revenue Structure
4.8.4 Gross Margin
4.8.6 DNA Sequencing
4.8.7 Development Prospects
4.9 Agilent Technologies
4.9.3 Revenue Structure
4.9.5 DNA Sequencing
4.10 Berry Genomics
4.10.2 DNA Sequencing
4.11 Hunan China Sun Pharmaceutical Machinery
4.11.2 DNA Sequencing
4.12 Jilin Zixin Pharmaceutical Industrial
4.12.3 DNA Sequencing
DNA Sequencing Industry Chain
DNA Sequencing Technology Application by Field
Features of DNA Sequencing Technology and its Advantage and Disadvantage by Generation
Trend in Sequencing Cost per Genome, 2001-2014
Trend in Sequencing Cost per Megabase, 2001-2014
Industry Chain Distribution of Major Global DNA Sequencing Enterprises
Major M&As in Global DNA Sequencing Industry, 2007-2014
Trend in The DDBJ Nucleotide Sequence Database, 2002-2014
Trend in The DDBJ Nucleotide Sequence Database Structure, 2002-2014
Top 30 DDBJ Organisms by Number of Nucleotides as of Mar. 2014
Next-generation DNA Sequencing Data of GenBank, 2008-2014
Worldwide Top 30 Countries or Regions with Next-generation DNA Sequencer by Number of Centers as of Sept. 2014
Global Next-Generation DNA Sequencer Distribution by Center as of Sept. 2014
Global Next-Generation DNA Sequencer Market Structure by Product as of Sept. 2014
Global Next-Generation DNA Sequencing Market Structure by Enterprise as of Sept. 2014
Global Next-Generation DNA Sequencing Market Structure by Number of Generation as of Sept. 2014
Global Next-Generation DNA Sequencer Distribution by Region as of Sept. 2014
Worldwide Top 30 Countries or Regions by Number of Next-Generation DNA Sequencers as of Sept. 2014
Next-Generation DNA Sequencer Market Structure of Global Genome Centers by Product as of Sept. 2014
Top 10 Global Genome Centers by Number of Next-Generation DNA Sequencers as of Sept. 2014
Global DNA Sequencing Market Size and YoY Growth, 2009-2017E
Global DNA Sequencing Market Structure by Type, 2013
Global DNA Sequencing Market Structure, 2017E
Global DNA Sequencing Target Market Potential
Policies on China DNA Sequencing industry, 2012-2014
China Next-generation DNA Sequencer Proportion in Global Market as of Sept. 2014
Revenue and Net Income of Illumina, 2007-2014
Revenue Structure of Illumina by Business, 2007-2013
Revenue Breakdown of Illumina by Region, 2007-2013
Gross Margin Trends of Illumina, 2007-2014
R&D Costs and % of Total Revenue of Illumina, 2007-2014
Illumina’s M&A History, 2007-2014
Illumina’s DNA Sequencers and Consumables (by Type) and Their Application
Revenue and Net Income of Illumina, 2014-2017E
Revenue and Net Income of Thermo Fisher Scientific, 2009-2014
Revenue Breakdown of Thermo Fisher Scientific by Business, 2009-2014
Revenue Breakdown of Thermo Fisher Scientific by Region, 2010-2013
Operating Margin of Thermo Fisher Scientific by Business, 2009-2014
R&D Costs and % of Total Revenue of Thermo Fisher Scientific, 2009-2014
Revenue and YoY Growth of Life Technologies, 2009-2013
Revenue and YoY Growth of Thermo Fisher Scientific in China, 2009-2013
Revenue and Net Income of Thermo Fisher Scientific, 2014-2017E
Revenue and YoY Growth of BGI, 2007-2013
Events of BGI’s DNA Sequencing Industry Layout, 1999-2014
Roche’s Revenue from Molecular Diagnosis and % of Total Revenue, 2009-2014
Roche’s Newly-released DNA Sequencing Products, 2012-2013
Revenue and Net Income of Qiagen, 2009-2014
Revenue Breakdown of Qiagen by Business, 2009-2014
Revenue Structure of Qiagen by Application, 2011-2014
Revenue Breakdown of Qiagen by Region, 2009-2013
R&D Costs and % of Total Revenue of Qiagen, 2009-2014
Revenue and Net Income of Pacific Biosciences, 2009-2014
Revenue Breakdown of Pacific Biosciences by Region, 2009-2013
R&D Costs and % of Total Revenue of Pacific Biosciences, 2009-2014
Pacific Biosciences’ Revenue from DNA Sequencing by Product, 2011-2014
Revenue and Net Income of Sequenom, 2009-2014
Revenue Breakdown of Sequenom by Segment, 2009-2014
Revenue Breakdown of Sequenom by Region, 2009-2013
Operating Margin of Sequenom by Segment, 2009-2014
R&D Costs and % of Total Revenue of Sequenom, 2009-2014
Sequenom’s Revenue from Gene Analysis by Segment, 2010-2013
Revenue and Net Income of DAAN Gene, 2009-2014
Revenue Breakdown of DAAN Gene by Business, 2009-2014
Revenue Breakdown of DAAN Gene by Region, 2009-2014
Gross Margin of DAAN Gene by Business, 2009-2014
R&D Costs and % of Total Revenue of DAAN Gene, 2009-2014
Revenue and Net Income of Agilent Technologies, FY2009-FY2014
Revenue Breakdown of Agilent Technologies by Business, FY2011-FY2014
Revenue Breakdown of Agilent Technologies by Region, FY2011-FY2013
R&D Costs and % of Total Revenue of Agilent Technologies, 2009-2014
Revenue and Net Income of DAAN Gene, 2014-2017E
Major Events of Berry Genomics, 2010-2014
DNA Sequencing Products of Berry Genomics
Revenue and Net Income of Hunan Honghao Gene, 2012-2014
Hunan Honghao Gene‘s Medical Devices Registered Based on Gene Chip, 2012-2014
Revenue and Net Income of Jilin Zixin Pharmaceutical Industrial, 2009-2014
Development History of DNA Sequencing of Jilin Zixin Pharmaceutical Industrial, 2010-2014
China Vacuum Blood Collection Industry Report, 2014-2017
The vacuum blood collection system consisting of vacuum blood collection tubes, disposable blood collection needles, tourniquets, etc transfers human venous blood to closed containers and makes it int...
China Pharmaceutical Excipients Industry Report, 2014-2017
Pharmaceutical excipients refer to adjuvants and additives used for production of pharmaceuticals and compounding of prescriptions. In addition to active ingredients, pharmaceutical excipients are als...
China Recombinant Protein Drug Industry Report, 2014-2017
The Chinese recombinant protein drug market has been expanding rapidly owing to the improvement of demand rigidity, consumption ability and the like. During 2005-2013, sales of recombinant protein dru...
China Heparin Industry Report, 2014-2017
As the world's major heparin API producer and exporter, China boasts enormous raw materials, which provides a strong support for the production of China’s heparin products. In 2013, the live pigs rais...
Global and China Monoclonal Antibody Industry Report, 2014-2019
Despite world-wide economic downturn and great changes in exchange rate, benefiting from robust market demand, global monoclonal antibody market size exceeded USD 80 billion in 2013, still one of biot...
Global and China DNA Sequencing Industry Research Report, 2014-2017
DNA sequencing is the process of reading nucleotide bases in a specific DNA molecule, that is to say determining the arrangement mode of adenine, thymine, cytosine, and guanine. It can be applied in a...
Global and China Stem Cell Industry Report, 2014-2017
Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. Stem cell therapy can be applied to treatmen...
China Human Vaccine Industry Report, 2014-2017
Vaccines can prevent and control infectious diseases, so the demand for these biological products is relatively rigid. In 2013, China’s human vaccine lot release volume grew by 4.9% from a year earlie...
China Blood Product Industry Report, 2014-2017
Plasma resource reserves and control are crucial to the development of blood products industry. Although the closure of 16 plasma collection stations in Guizhou in 2011 didn’t cause major disruption t...
China Animal Vaccine Industry Report, 2013-2016
Animal vaccine is a kind of biological agent that enables inoculated animals to produce active immunity for disease prevention. Europe and the United States and other developed countries are the main ...
China Contract Research Organization (CRO) Industry Report, 2013-2016
China CRO industry has developed rapidly in recent years, registering a CAGR of 27.2% during 2007-2013, of which the market size reached RMB 36 billion in 2013, occupying 10% of global market share.
Global and China Biodegradable Plastics Industry Report, 2013-2016
Global biodegradable plastic production and demand have grown rapidly in recent years, and the capacity reached 1-1.5 million t/a in 2012-2013. Among dozens of biodegradable plastic varieties develope...
Global and China Industrial Enzyme Industry Report, 2014-2016
In 2007-2013, the global industrial enzyme market size grew at the CAGR of 5.7%, reaching USD4.04 billion in 2013, 1.4 times that in 2007. The global industrial enzyme market is monopolized by a small...
China Heparin Industry Report, 2013-2015
Since the small intestines of pigs (raw materials for production of heparin) in China are abundant (the pig slaughtering volume in China approximates 50% of globe’s total) and heparin APIs are gradual...
China Lactic Acid and Derivative Industry Report, 2013
China’s lactic acid capacity and output continued to grow at the respective CAGR of 22.7% and 28.7% in 2007-2011. But limited by market demand, the annual output of most vendors was below their design...
China Human Vaccine Industry Report, 2012-2015
In the wake of China's economic growth and enhanced disease prevention awareness, Chinese human vaccine market has been expanding. In 2012, Chinese human vaccine market valued RMB10.5 billion with the...
China Blood Product Industry Report, 2012-2015
Plasma is a key raw material of the blood product industry. In August 2011, China shut down 16 plasma stations in Guizhou, resulting in a decrease of 15% in the plasma volume of the year. However, due...
China Animal Vaccine Industry Report, 2012-2015
In view of the frequent occurrence of animal epidemic diseases over the years, the Chinese government has increased investment in epidemic prevention and implemented compulsory immunization system. Be...